WO2017156423A3 - Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever - Google Patents
Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever Download PDFInfo
- Publication number
- WO2017156423A3 WO2017156423A3 PCT/US2017/021842 US2017021842W WO2017156423A3 WO 2017156423 A3 WO2017156423 A3 WO 2017156423A3 US 2017021842 W US2017021842 W US 2017021842W WO 2017156423 A3 WO2017156423 A3 WO 2017156423A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- filovirus
- treatment
- hemorrhagic fever
- protective antibody
- antibody cocktails
- Prior art date
Links
- 241000711950 Filoviridae Species 0.000 title abstract 3
- 206010061192 Haemorrhagic fever Diseases 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000007136 Filoviridae Infections Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
This disclosure provides a method for preventing, treating, or managing a filovirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least two anti-filovirus glycoprotein antibodies or antigen-binding fragments thereof where at least one of the antibodies or fragments binds to its orthologous filovirus glycoprotein epitope on two or more filovirus species or strains.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307118P | 2016-03-11 | 2016-03-11 | |
US62/307,118 | 2016-03-11 | ||
US201662368688P | 2016-07-29 | 2016-07-29 | |
US62/368,688 | 2016-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017156423A2 WO2017156423A2 (en) | 2017-09-14 |
WO2017156423A3 true WO2017156423A3 (en) | 2017-10-19 |
Family
ID=59789746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/021842 WO2017156423A2 (en) | 2016-03-11 | 2017-03-10 | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017156423A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018057916A1 (en) * | 2016-09-24 | 2018-03-29 | The Trustees Of The University Of Pennsylvania | Novel humanized anti-ebola antibodies useful in preventing ebola infections |
AU2018221172A1 (en) * | 2017-02-17 | 2019-09-05 | Adimab, Llc | Monoclonal antibodies and cocktails for treatment of Ebola infections |
EP3583122A4 (en) * | 2017-02-17 | 2020-11-11 | Mapp Biopharmaceutical, Inc. | Monoclonal antibodies and cocktails for treatment of ebola infections |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120014958A1 (en) * | 2008-06-25 | 2012-01-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
US20150232556A1 (en) * | 2012-09-19 | 2015-08-20 | Innate Pharma | Kir3dl2 binding agents |
WO2015200522A2 (en) * | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
WO2016069627A1 (en) * | 2014-10-28 | 2016-05-06 | Integrated Biotherapeutics, Inc. | Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins |
WO2016145385A2 (en) * | 2015-03-11 | 2016-09-15 | Integrated Biotherapeutics, Inc. | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails |
WO2016179511A1 (en) * | 2015-05-07 | 2016-11-10 | Mapp Biopharmaceutical, Inc. | Monoclonal antibody cocktails for treatment of ebola infections |
US20170088606A1 (en) * | 2013-06-03 | 2017-03-30 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
-
2017
- 2017-03-10 WO PCT/US2017/021842 patent/WO2017156423A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120014958A1 (en) * | 2008-06-25 | 2012-01-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
US20150232556A1 (en) * | 2012-09-19 | 2015-08-20 | Innate Pharma | Kir3dl2 binding agents |
US20170088606A1 (en) * | 2013-06-03 | 2017-03-30 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
WO2015200522A2 (en) * | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
WO2016069627A1 (en) * | 2014-10-28 | 2016-05-06 | Integrated Biotherapeutics, Inc. | Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins |
WO2016145385A2 (en) * | 2015-03-11 | 2016-09-15 | Integrated Biotherapeutics, Inc. | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails |
WO2016179511A1 (en) * | 2015-05-07 | 2016-11-10 | Mapp Biopharmaceutical, Inc. | Monoclonal antibody cocktails for treatment of ebola infections |
Non-Patent Citations (2)
Title |
---|
MURIN, CD ET AL.: "Structures of protective antibodies reveal sites of vulnerability on Ebola virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 111, no. 48, 2 December 2014 (2014-12-02), pages 17182 - 17187, XP055321303 * |
SUNDLING, C ET AL.: "Single- cell and deep sequencing of IgG-switched macaque B cells reveal a diverse immunoglobulin repertoire following immunization", JOURNAL OF IMMUNOLOGY, vol. 192, no. 8, 15 April 2015 (2015-04-15), pages 3637 - 3644, XP055432919 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017156423A2 (en) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016145385A3 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
WO2018170351A8 (en) | Anti-phf-tau antibodies and uses thereof | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
WO2015143123A3 (en) | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof | |
WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
WO2015200806A3 (en) | Humanized anti-tau antibodies | |
WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2016062722A8 (en) | Combination | |
MX2019007848A (en) | Anti-pd-1 antibodies and uses thereof. | |
PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
TW201613575A (en) | Treatment of polybacterial infections | |
MX2018009498A (en) | Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes. | |
WO2015120097A3 (en) | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof | |
WO2017075188A3 (en) | Methods of using anti-alpha toxin antibody | |
EP4273165A3 (en) | Interferon beta antibodies and uses thereof | |
WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same | |
PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
WO2017156423A3 (en) | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever | |
UY36820A (en) | SPECIFIC MONOCLONAL ANTIBODIES FOR ANTIGEN P OF HUMAN SYNCHRIRY RESPIRATORY VIRUS (VRSH), PRODUCED AND SECRETED BY CELLULAR HYBRIDIDES, USEFUL FOR DETECTION AND DIAGNOSIS OF INFECTION CAUSED BY VRS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17764204 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17764204 Country of ref document: EP Kind code of ref document: A2 |